Johnson And Johnson (JNJ) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 28 2026 to Jun 29 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Johnson and Johnson  (NYSE: JNJ)


Johnson And Johnson's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Johnson And Johnson's ROA in the second quarter of 2026?
Johnson and Johnson achieved a return on average assets (ROA) of 10.43 % in its second quarter of 2026, which is below Johnson And Johnson's average return on assets, which stands at 12.03%.

ROA fell compared to the first quarter of 2026, despite the net income growth of 5.71% from the first quarter of 2026.

However, within the Healthcare sector 92 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2026 from 461 to 572.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 28 2026)
II. Quarter		 (Mar 29 2026)
I. Quarter		 (Dec 28 2025)
IV. Quarter		 (Sep 28 2025)
III. Quarter		 (Jun 29 2025)
II. Quarter
Y / Y Total Assets Change 10.53 % 3.73 % 17.43 % 14.13 % 12.38 %
Y / Y Net Income Change -0.05 % -52.4 % 49.11 % 91.24 % 18.16 %
Net Income (TTM) in million 21,037 21,040 26,804 25,119 22,661
Return On Assets (TTM) 10.43 % 10.7 % 13.76 % 13.41 % 12.49 %
JNJ's Total Ranking # 572 # 461 # 430 # 468 # 487
Total Assets (TTM) in million 213,745 200,894 199,210 192,816 193,389
Seq. Total Assets Change 6.4 % 0.85 % 3.32 % -0.3 % -0.15 %
Seq. Net Income Change 5.71 % 2.33 % -0.7 % -6.95 % -49.66 %

JNJ's 5 Years Annual ROA >> Back to JNJ Management Effectiveness >> Compare JNJ ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 39
Sector # 93
Overall # 570

Return On Assets Statistics
High Average Low
22.15 %
12.03 %
0.8 %
(Jun 30 2024)   (Apr 01 2018)



  News about Johnson and Johnson Return on Assets ROA

Johnson & Johnsons Bold U.S. Investment Plans Amidst Mixed Financial Performance

In a bold move that reflects its commitment to innovation and growth, Johnson and Johnson (NYSE: JNJ) announced a significant expansion of its investment footprint in the United States. Over the next four years, the healthcare giant plans to allocate more than $55 billion towards advancements in manufacturing, research and development (RandD), and technology a 25% increase compared to the previous four-year investment cycle. This initiative builds upon the company s existing elevated U.S. investment levels, which have been positively influenced by policy changes like the 2017 tax reform.The announcement showcases Johnson and Johnson s position as a leader in the healthcare industry, underscoring its role as a comprehensive innovation powerhouse. The investments aim not only to bolster domestic manufacturing capabilities but also to drive cutting-edge research that can lead to new therapeutic breakthroughs. This move aligns with broader industry trends emphasizing local production and innovation to improve healthcare outcomes.



Financial Statements
Johnson And Johnson's Assets $ 213,745 million JNJ's Balance sheet
Johnson And Johnson's Income $ 5,534 million Quarterly JNJ's Income Statement
JNJ's Income by Division See JNJ's Income by Division



Annual Return On Assets (Dec 28 2025)
FY 2025		 (Dec 29 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Jan 01 2023)
FY 2022		 (Jan 02 2022)
FY 2021
Y / Y Total Assets Change 17.43 % 7.18 % -11.21 % 3.76 % 3.27 %
Total Assets in million 199,210 169,643 158,279 178,255 171,795
Y / Y Net Income Change 90.56 % -59.99 % 95.94 % -14.07 % 41.89 %
Net Income in million 26,804 14,066 35,153 17,941 20,878
Annual Return On Assets 13.46 % 8.29 % 22.21 % 10.06 % 12.15 %

JNJ's 5 Years Annual ROA >> Back to JNJ Management Effectiveness >> Compare JNJ ROA to its Competitors



Comment on JNJ's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 13.46 % compared to prior year, due to annual net income growth of 90.56 % to $26,804.00 million, while value of Johnson And Johnson's overall assets grew just by 17.43 % to $199,210.00 million, compared to $199,210.00 a year before.


More Return On Assets Ratios
JNJ's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
JNJ's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for JNJ's Competitors
Subscribers only: Roa for Johnson And Johnson's Suppliers
Subscribers only: Return On Assets for JNJ's Customers

You may also want to know
JNJ's Roi JNJ's Inventory Turnover Ratio JNJ's Growth Rates JNJ's Dividend Comparisons
JNJ's Profitability Ratios JNJ's Asset Turnover Ratio JNJ's Dividend Growth
JNJ's Roe JNJ's Valuation Ratios JNJ's Financial Strength Ratios JNJ's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 28 2026, within Healthcare Sector ROA
Indivior Pharmaceuticals Inc   28.21 %
Qhslab Inc   27.12 %
Adma Biologics Inc   26.58 %
Mettler toledo International Inc   24.86 %
Medpace Holdings Inc   24.84 %
Caredx Inc   24.81 %
Acadia Pharmaceuticals Inc   24.38 %
Eli Lilly And Company  21.97 %
Innoviva Inc   21.64 %
Vaxart Inc   20.85 %
Zevra Therapeutics Inc   20.39 %
Iradimed Corporation  20.36 %
Protalix Biotherapeutics inc   20.09 %
Pro dex Inc   19.87 %
Electromed Inc   19.39 %
United Therapeutics Corporation  17.98 %
Resmed Inc   17.80 %
Krystal Biotech Inc   17.65 %
Chemed Corporation  17.52 %
Zoetis Inc   17.19 %
Vertex Pharmaceuticals Inc  16.88 %
Halozyme Therapeutics Inc   16.55 %
Alnylam Pharmaceuticals Inc   15.76 %
Intuitive Surgical Inc   15.63 %
Healthcare Services Group Inc   15.21 %
Inspire Medical Systems inc   15.21 %
Dexcom Inc   14.87 %
Neurocrine Biosciences Inc   14.73 %
Entera Bio Ltd   14.60 %
Standard Biotools Inc   14.31 %

Date modified: 2026-09-26T07:18:34+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.